The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews

@article{Nielsen2018TheUO,
  title={The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews},
  author={Suzanne Nielsen and Rada Germanos and Megan Weier and John David Pollard and Louisa Degenhardt and Wayne D. Hall and Nicholas Buckley and Michael Farrell},
  journal={Current Neurology and Neuroscience Reports},
  year={2018},
  volume={18},
  pages={1-12}
}
Purpose of ReviewPharmaceutical cannabinoids such as nabiximols, nabilone and dronabinol, and plant-based cannabinoids have been investigated for their therapeutic potential in treating multiple sclerosis (MS) symptoms. This review of reviews aimed to synthesise findings from high quality systematic reviews that examined the safety and effectiveness of cannabinoids in multiple sclerosis. We examined the outcomes of disability and disability progression, pain, spasticity, bladder function… 
View on Springer
ses.library.usyd.edu.au
92 Citations
Highly Influential Citations
6
Background Citations
22
Methods Citations
3
Results Citations
1

92 Citations

Cannabinoids for the treatment of spasticity

Paediatric studies of spasticity provide low quality evidence and are inadequate to inform clinical practice, and should be considered in the context of the narrow therapeutic index of cannabinoids forSpasticity and adverse effects.

Systematic reviews of randomized controlled trials of cannabinoid products in chronic pain conditions and for symptoms associated with multiple sclerosis: what do they tell us?

The therapeutic effect of cannabinoids, as already demonstrated for some products, is not reflected clearly in the current range of systematic reviews and meta-analyses in chronic pain and MS.

The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms

Oromucosal spray and oral cannabis are mainly used for treating patients with MS and have positive effects on treating the most common symptoms of MS, such as pain and spasticity, whereas the other MS symptoms indicated slight improvement, for which further studies are needed.

Cost-Effectiveness of Medicinal Cannabis for Management of Refractory Symptoms Associated With Chronic Conditions: A Systematic Review of Economic Evaluations.

  • D. ErkuS. ShresthaP. Scuffham
  • Medicine, Political Science
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2021

A Systematic Review on Cannabinoids for Neuropathic Pain Administered by Routes Other than Oral or Inhalation

There is a significant lack of evidence indicating that cannabinoids administered by routes other than oral or inhaled may be an effective alternative, with better tolerance and safety in the treatment of neuropathic pain.

Medical Cannabis for Older Patients

A pragmatic clinical approach to a rational dialogue with older patients is proposed, highlighting the importance of individual benefit–risk assessment and shared patient–clinician decision making.

Cannabinoids in neuroinflammatory disorders: Focusing on multiple sclerosis, Parkinsons, and Alzheimers diseases.

This review will discuss an outline of the endocannabinoid system's involvement in neuroinflammatory disorders, and the pharmacological efficacy of different natural and synthetic preparations of phytocannabinoids acting on cannabinoid receptors, particularly in MS, PD, and AD will be updated.

Efficacy of cannabinoids for treating paediatric spasticity in cerebral palsy or traumatic brain injury: what is the evidence?

  • S. NielsenW. Hall
  • Medicine, Psychology
    Developmental medicine and child neurology
  • 2020
Until there is better evidence of effectiveness and safety in paediatric spasticity related to CP, it would be prudent not to use nabiximols to treat this condition, and the burden is placed on advocates of the use of nabixomols in this condition to provide better evidence.

Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis

Treatment efficacy was associated with baseline dementia severity and dose, but not dementia subtype, age, or sex, and preliminary evidence for the efficacy and tolerability of cannabinoids as treatments for NPS is found.

The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence

It is difficult to make a recommendation for the use of CBD in chronic pain management, but it is important to note that there are many CBD products currently available as supplements, but these products are non-pharmaceuticals and lack the appropriate clinical studies to support their efficacy claims.
...

References

SHOWING 1-10 OF 45 REFERENCES

Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review

Evidence is found that combined THC and CBD extracts may provide therapeutic benefit for MS spasticity symptoms and subjective assessment of symptom relief did often show significant improvement post-treatment.

Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.

There was moderate- quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity and low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome.

Role of Cannabinoids in Multiple Sclerosis

An increasing amount of evidence is now emerging to confirm anecdotal reports of symptomatic improvement, particularly for muscle stiffness and spasms, neuropathic pain and sleep and bladder disturbance, in patients with MS treated with cannabinoids.

Adverse effects of medical cannabinoids: a systematic review

Short-term use of existing medical cannabinoids appeared to increase the risk of nonserious adverse events, and high-quality trials of long-term exposure are required to further characterize safety issues related to the use of medical cannabinoids.

Cannabinoids in medicine: A review of their therapeutic potential.

Cannabinoids present an interesting therapeutic potential as antiemetics, appetite stimulants in debilitating diseases, analgesics, and in the treatment of multiple sclerosis, spinal cord injuries, Tourette's syndrome, epilepsy and glaucoma.

Cannabidiol in Humans—The Quest for Therapeutic Targets

Preliminary clinical trials suggest that high-dose oral CBD may exert a therapeutic effect for social anxiety disorder, insomnia and epilepsy, but also that it may cause mental sedation.

Cannabinoids in the treatment of movement disorders: A systematic review of case series and clinical trials

Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis

Treatment efficacy was associated with baseline dementia severity and dose, but not dementia subtype, age, or sex, and preliminary evidence for the efficacy and tolerability of cannabinoids as treatments for NPS is found.

Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders

A systematic review of medical marijuana to address treatment of symptoms of multiple sclerosis, epilepsy, and movement disorders found oral cannabinoids are of unknown efficacy in non–chorea-related symptoms of Huntington disease, Tourette syndrome, cervical dystonia, and epilepsy.

Role of Cannabinoids in the Treatment of Pain and (Painful) Spasticity

Patients with unsatisfactory response to other methods of pain therapy and who were characterized by failed stress adaptation particularly benefited from treatment with cannabinoids, but none of the attempts to overcome the disadvantage of the narrow therapeutic index have resulted in a major breakthrough.